Skip to main content
Top
Published in: Pathology & Oncology Research 2/2020

Open Access 01-04-2020 | Original Article

All Benign and Malignant Apocrine Breast Lesions Over-Express Claudin 1 and 3 and Are Negative for Claudin 4

Authors: Sami Shousha, Oliver Anscombe, Taneisha McFarlane

Published in: Pathology & Oncology Research | Issue 2/2020

Login to get access

Abstract

Invasive apocrine carcinoma of the breast is an uncommon triple negative tumour that lacks a specific therapeutic target. Apocrine metaplasia of the breast shares common morphological features with apocrine carcinoma, and was previously found to consistently over-express claudin 1 and to lack claudin 4. This study was aimed at finding whether apocrine carcinoma, and other related apocrine breast lesions, have similar claudin profile. The immunohistochemical expression of claudin 1, 3 and 4 was studied in 11 cases of in situ and invasive apocrine breast carcinoma, 7 benign apocrine lesions and 45 consecutive morphologically non-apocrine triple negative breast carcinomas. All cases were also immunostained for Gross Cystic Disease Fluid Protein-15 (GCDFP-15), a marker for apocrine differentiation. Apocrine breast lesions maintained their expression pattern from benign through DCIS to invasive carcinoma; all showing strong expression of claudin 1 and 3 and absence of claudin 4. The same pattern of expression was seen in 2 out of the 45 morphologically non-apocrine tumours, but both showed strong positive staining for GCDFP-15. It is concluded that all benign and malignant apocrine lesions of the breast have a consistent pattern of claudin 1, 3 and 4 expression, suggesting the presence of a specific pathway for the development of invasive apocrine carcinoma. The over-expression of claudin 1 and 3 may have therapeutic implications as targets for managing apocrine cancers.
Literature
1.
go back to reference Kwon MJ (2013) Emerging roles of claudins in human cancer. Int J Mol Sci 14:18148–18181CrossRef Kwon MJ (2013) Emerging roles of claudins in human cancer. Int J Mol Sci 14:18148–18181CrossRef
2.
go back to reference Bleich M, Gunzel D (2017) Physiology, pathophysiology and clinical impact of claudins. Pflugers Arch 469:1–2CrossRef Bleich M, Gunzel D (2017) Physiology, pathophysiology and clinical impact of claudins. Pflugers Arch 469:1–2CrossRef
4.
go back to reference Osanai M, Takasawa A, Murata M, Sawada N (2017) Claudins in cancer. Pflugers Arch 469:55–67CrossRef Osanai M, Takasawa A, Murata M, Sawada N (2017) Claudins in cancer. Pflugers Arch 469:55–67CrossRef
6.
go back to reference Kominsky SL, Argani P, Korz D, Evron E, Raman V, Garrett E, Rein A, Sauter G, Kallioniemi OP, Sukumar S (2003) Loss of the tight junction protein claudin-7 correlates with histological grade in both ductal carcinoma in situ and invasive ductal cartcinoma of the breast. Oncogene 22:2021–2033CrossRef Kominsky SL, Argani P, Korz D, Evron E, Raman V, Garrett E, Rein A, Sauter G, Kallioniemi OP, Sukumar S (2003) Loss of the tight junction protein claudin-7 correlates with histological grade in both ductal carcinoma in situ and invasive ductal cartcinoma of the breast. Oncogene 22:2021–2033CrossRef
7.
go back to reference Blanchard AA, Skliris GP, Watson P, Murphy LC, Penner C, Tomes L et al (2009) Claudin 1, 3, and 4 protein expression in ER negative breast cancer correlates with markers of the basal phenotype. Virchows Arch 454:647–656CrossRef Blanchard AA, Skliris GP, Watson P, Murphy LC, Penner C, Tomes L et al (2009) Claudin 1, 3, and 4 protein expression in ER negative breast cancer correlates with markers of the basal phenotype. Virchows Arch 454:647–656CrossRef
8.
go back to reference Kulka J, Szasz AM, Nemeth Z, Madaras L, Schaff Z, Molnar IA et al (2009) Expression of tight junction protein claudin-4 in basal-like breast carcinoma. Pathol Oncol Res 15:59–64CrossRef Kulka J, Szasz AM, Nemeth Z, Madaras L, Schaff Z, Molnar IA et al (2009) Expression of tight junction protein claudin-4 in basal-like breast carcinoma. Pathol Oncol Res 15:59–64CrossRef
9.
go back to reference Lanigan F, McKiernan E, Brennan DJ, Hegarty S, Millikan RC, McBryan J, Jirstrom K, Landberg G, Martin F, Duffy MJ, Gallagher WM (2009) Increased claudin-4 expression is associated with poor prognosis and high tumour grade in breast cancer. Int J Cancer 124:2088–2097CrossRef Lanigan F, McKiernan E, Brennan DJ, Hegarty S, Millikan RC, McBryan J, Jirstrom K, Landberg G, Martin F, Duffy MJ, Gallagher WM (2009) Increased claudin-4 expression is associated with poor prognosis and high tumour grade in breast cancer. Int J Cancer 124:2088–2097CrossRef
11.
go back to reference Gerhard R, Ricardo S, Albergaria A, Gomes M, Silva AR, Logullo AF, Cameselle-Teijeiro JF, Paredes J, Schmitt F (2012) Immunohistochemical features of claudin-low intrinsic subtype in metaplastic breast carcinomas. Breast 21:354–360CrossRef Gerhard R, Ricardo S, Albergaria A, Gomes M, Silva AR, Logullo AF, Cameselle-Teijeiro JF, Paredes J, Schmitt F (2012) Immunohistochemical features of claudin-low intrinsic subtype in metaplastic breast carcinomas. Breast 21:354–360CrossRef
12.
go back to reference Blanchard AA, Ma X, Dueck KJ, Penner C, Cooper SC, Mulhall D, Murphy LC, Leygue E, Myal Y (2013) Cladin 1 expression in basal-like breast cancer is related to patient age. BMC Cancer 13:268CrossRef Blanchard AA, Ma X, Dueck KJ, Penner C, Cooper SC, Mulhall D, Murphy LC, Leygue E, Myal Y (2013) Cladin 1 expression in basal-like breast cancer is related to patient age. BMC Cancer 13:268CrossRef
13.
go back to reference Lu S, Singh K, Mangray S, Tavares R, Noble L, Resnick M et al (2013) Claudin expression in high grade invasive ductal carcinoma of the breast: correlation with the molecular type. Modern Pathol 26:485–495CrossRef Lu S, Singh K, Mangray S, Tavares R, Noble L, Resnick M et al (2013) Claudin expression in high grade invasive ductal carcinoma of the breast: correlation with the molecular type. Modern Pathol 26:485–495CrossRef
14.
go back to reference Van Voss MRH, van Diest PJ, Smolders YHCM, Bart J, van der Wal E, van der Groep. Distinct claudin expression characterizes BRCA1=related breast cancer. Histopathology 2014;65:814–827CrossRef Van Voss MRH, van Diest PJ, Smolders YHCM, Bart J, van der Wal E, van der Groep. Distinct claudin expression characterizes BRCA1=related breast cancer. Histopathology 2014;65:814–827CrossRef
15.
go back to reference Zhou B, Moodie A, Blanchard AA, Leygue E, Myal Y (2015) Claudin 1 in breast cancer: new insights. J Clin Med 4:1960–1976CrossRef Zhou B, Moodie A, Blanchard AA, Leygue E, Myal Y (2015) Claudin 1 in breast cancer: new insights. J Clin Med 4:1960–1976CrossRef
17.
go back to reference Ma F, Ding X, Fan Y, Ying J, Zheng S, Lu N, Xu B (2014) A CLDN1-negative phenotype predicts poor prognosis in triple negative breast cancer. PLoS One 9(11):e112765CrossRef Ma F, Ding X, Fan Y, Ying J, Zheng S, Lu N, Xu B (2014) A CLDN1-negative phenotype predicts poor prognosis in triple negative breast cancer. PLoS One 9(11):e112765CrossRef
18.
go back to reference Morohashi S, Kusumi T, Sato F, Odagiri h CH, Yoshihara S et al (2007) Decreased expression of claudin-1 correlates with recurrence status in breast cancer. Int J Mol Med 20:139–143PubMed Morohashi S, Kusumi T, Sato F, Odagiri h CH, Yoshihara S et al (2007) Decreased expression of claudin-1 correlates with recurrence status in breast cancer. Int J Mol Med 20:139–143PubMed
19.
go back to reference Abd-Elazeem MA, Abd-Elazeem MA (2015) Claudin 4 expression in triple negative breast cancer: correlation with androgen receptors and Ki-67 expression. Ann Diag Pathol 19:37–42CrossRef Abd-Elazeem MA, Abd-Elazeem MA (2015) Claudin 4 expression in triple negative breast cancer: correlation with androgen receptors and Ki-67 expression. Ann Diag Pathol 19:37–42CrossRef
20.
go back to reference Soini Y (2004) Claudin 2, 3, 4 and 5 in Paget’s disease and breast carcinoma. Hum Pathol 35:1531–1536CrossRef Soini Y (2004) Claudin 2, 3, 4 and 5 in Paget’s disease and breast carcinoma. Hum Pathol 35:1531–1536CrossRef
21.
go back to reference Lin X, Shang X, Manorek G, Howell SB (2013) Regulation of the epithelial-mesenchymal transition by claudin-3 and claudi-4. PLoS One 8(6):e67496CrossRef Lin X, Shang X, Manorek G, Howell SB (2013) Regulation of the epithelial-mesenchymal transition by claudin-3 and claudi-4. PLoS One 8(6):e67496CrossRef
22.
go back to reference Gromov P, Espinoza JA, Gromova I (2015) Molecular and diagnostic features of apocrine breast lesions. Expert Rev Mol Diagn 15(8):1011–1022CrossRef Gromov P, Espinoza JA, Gromova I (2015) Molecular and diagnostic features of apocrine breast lesions. Expert Rev Mol Diagn 15(8):1011–1022CrossRef
23.
go back to reference Vranic S, Merchio C, Castellano I, Botta C, Scalzo MS, Bender RP et al (2015) Immunohistochemical and molecular profiling of histologically defined apocrine carcinoma of the breast. Hum Pathol 45:1350–1359CrossRef Vranic S, Merchio C, Castellano I, Botta C, Scalzo MS, Bender RP et al (2015) Immunohistochemical and molecular profiling of histologically defined apocrine carcinoma of the breast. Hum Pathol 45:1350–1359CrossRef
24.
go back to reference Mills AM, Gottlieb CE, Wendroth SM, Brenin CM, Atkins KA (2016) Pure apocrine carcinomas represent a clinicopathologically distinct androgen receptor-positive subset of triple-negative breast cancers. Am J Surg Pathol 40:1109–1116CrossRef Mills AM, Gottlieb CE, Wendroth SM, Brenin CM, Atkins KA (2016) Pure apocrine carcinomas represent a clinicopathologically distinct androgen receptor-positive subset of triple-negative breast cancers. Am J Surg Pathol 40:1109–1116CrossRef
25.
go back to reference Hoevel T, Macer R, Mundigl O, Swisshelm K, Kubbies M (2002) Expression and targeting of the tight junction protein CLDN1 in CLDN1- negative human breast tumour cells. J Cell Physiol 191:60–68CrossRef Hoevel T, Macer R, Mundigl O, Swisshelm K, Kubbies M (2002) Expression and targeting of the tight junction protein CLDN1 in CLDN1- negative human breast tumour cells. J Cell Physiol 191:60–68CrossRef
26.
go back to reference Moldvay J, Fabian K, Jacket M, Nemeth Z, Bogos K, Furak J et al (2017) Claudin-1 protein expression is a good prognostic factor in non-small cell lung cacer, but only in squamous cell carcinoma cases. Pathol Oncol Res 23:151–156CrossRef Moldvay J, Fabian K, Jacket M, Nemeth Z, Bogos K, Furak J et al (2017) Claudin-1 protein expression is a good prognostic factor in non-small cell lung cacer, but only in squamous cell carcinoma cases. Pathol Oncol Res 23:151–156CrossRef
Metadata
Title
All Benign and Malignant Apocrine Breast Lesions Over-Express Claudin 1 and 3 and Are Negative for Claudin 4
Authors
Sami Shousha
Oliver Anscombe
Taneisha McFarlane
Publication date
01-04-2020
Publisher
Springer Netherlands
Published in
Pathology & Oncology Research / Issue 2/2020
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-019-00662-9

Other articles of this Issue 2/2020

Pathology & Oncology Research 2/2020 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine